

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael C. Montalto, et al.

Group Art Unit: 1616

Serial No.: 10/747,715

Examiner: D. L. Jones

Filed: December 26, 2003

For COMPOSITIONS AND METHODS FOR  
NON-INVASIVE IMAGING OF SOLUBLE  
BETA-AMYLOIDSUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

- ☐ 1 Pursuant to 37 CFR 1.97(b)  
[within 3 months of national, non-CPA filing or prior to 1st Office Action] *no charge*
- ☐ 2 Certification Pursuant to 37 CFR 1.97(c)(1)  
[before Final Office Action, Allowance, or other action closing prosecution] *no charge*
- ☒ 3 Fee Payment Pursuant to 37 CFR 1.97(c)(2)  
[before Final Office Action, Allowance, or other action closing prosecution] *\$180.00*
- ☐ 4 Certification & Fee Payment Pursuant to 37 CFR 1.97(d)  
[On or before issue fee payment] *\$180.00*

ATTN: MAILSTOP AMENDMENT  
COMMISSIONER FOR PATENTS  
PO BOX 1450, ALEXANDRIA, VA 22313-1450

Sir:

The following are submitted in the above identified application in compliance with 37 CFR 1.97 &amp; 37 CFR 1.98:

- ☒ 5 A list of documents on form PTO-1449 or Substitute together with copies of each identified document and a translation thereof or a concise explanation of each non-English language document or a Search Report from an International Searching Authority for a patent application filed via the Patent Cooperation Treaty or document(s) cited in the application or the priority application.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Date of Deposit

Type or Print Name

Signature

03/10/2006 H8UTERAI 00000031 070850

10747715

01 FC:1806

180.00 DA

This paper is submitted in accordance with:

- ☐ 6 37 CFR 1.97(b): [within 3 months of national, non-CPA filing or prior to 1st Office Action]
- ☒ 7 37 CFR 1.97(c): [before Final Office Action, Allowance, or other action closing prosecution, whichever is earlier]; and
- ☐ 8 The required Certification made in item 11 below; or
- ☒ 9 The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 15 below.
- ☐ 10 37 CFR §1.97(d): [On or before issue fee payment]; and
- a) The required Certification is stated in item 11 below; and
- b) The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 14 below.
- ☐ 11 Certification
- ☐ 12 Each item of information contained in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; or
- ☐ 13 No item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this document after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR 1.56(c) more than three (3) months prior to the filing of this Statement.
- ☒ 14 Payment of all applicable fees:
- ☒ 15 Please charge all applicable fees associated with the submittal of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 07-0868. An original and two (2) copies of this document are enclosed.

March 3, 2006

Date

General Electric Company  
GEGR Patent Docket Rm. Bldg. K-1 Rm. 4A59  
One Research Circle  
Niskayuna, New York 12309  
Customer Number: 006147

Respectfully submitted,

Maureen A. Bresnahan

Attorney - Maureen A. Bresnahan

Registration No. 44,559

Phone: (518) 387-6304

or (518) 387-7122



OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PT  
O/SB/08B (07-05) Approved for use  
through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT

Substitute for form 1449/PTO **INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

**Complete if Known**

Application Number	10/747,715
Filing Date	12/26/03
First Named Inventor	Michael C. Montalto
Art Unit	1616
Examiner Name	Dameron L. Jones
Attorney Docket Number	133658-2

(Use as many sheets as necessary)

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sub>2</sub>
	AA	Maria M. Pi ken, M.D., Ph.D., "The Changing Concepts of Amyloid", <i>Arch Pathol Lab Med.</i> , 2001; 125, pp. 8-9, 40-43.	<input type="checkbox"/>
	AB	G.W. Small, et al., "In Vivo Brain Imaging of Tangle Burden In Humans", <i>Journal of Molecular Neuroscience</i> , 2002; 19, pp. 323-327.	<input type="checkbox"/>
	AC	C.A. Mathis, et al., "A Lipophilic Thioflavin-T Derivative for Positron Emission Tomography (PET) Imaging of Amyloid in Brain", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 2002; 12, pp. 295-298.	<input type="checkbox"/>
	AD	W.E. Klunk, et al., "Quantifying Amyloid $\beta$ -Peptide ( $A\beta$ ) Aggregation Using the Congo Red- $A\beta$ (CR- $A\beta$ ) Spectrophotometric Assay", <i>Analytical Biochemistry</i> , 1999; 266, pp. 66-76.	<input type="checkbox"/>
	AE	C.A. Mathis, Ph.D., et al., "Imaging Technology for Neurodegenerative Diseases-Progress Toward Detection of Specific Pathologies", <i>Arch neurol</i> , 2005; 62, pp. 196-200.	<input type="checkbox"/>
	AF	N Okamura, et al., "A Novel Imaging Probe for In Vivo Detection of Neuritic and Diffuse Amyloid Plaques in the Brain", <i>Journal of Molecular Neuroscience</i> , 2004; 24, pp. 247-255.	<input type="checkbox"/>
	AG	M. Sunde, et al., "Common Core Structure of Amyloid Fibrils by Synchrotron X-ray Diffraction", <i>J. Mol. Biol</i> , 1997; 273, pp. 729-739.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.